Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
Patients with pathologically or cytologically confirmed neuroendocrine tumors;
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
Life expectancy ≥ 12 weeks;
Adequate organ and bone marrow function
Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
Advanced neuroendocrine tumor
Cohort
Prospective
Surufatinib Administration
DrugSurufatinib as monotherapy or combination therapy, at the discretion of the investigator based on the patient's overall condition.
Progression-free survival (PFS)
the time from the date of first study treatment to the date of first documented tumor progression (assessed according to RECIST version 1.1) or death due to any cause, whichever occurs first.
Objective response rate (ORR)
the proportion of patients with complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria in the analysis population.
Click on the lead sponsor to view all of their trials.
Yefeng
Lead sponsor
The First Affiliated Hospital of Xiamen University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
